Delcath Systems, Inc. (DCTH)
| Market Cap | 225.90M |
| Revenue (ttm) | 4.61M |
| Net Income (ttm) | -49.79M |
| Shares Out | 27.79M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399,520 |
| Open | 7.47 |
| Previous Close | 7.57 |
| Day's Range | 7.47 - 8.12 |
| 52-Week Range | 2.25 - 8.18 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 20.20 (+148.92%) |
| Earnings Date | May 14, 2024 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]
Financial Performance
In 2023, DCTH's revenue was $2.07 million, a decrease of -24.05% compared to the previous year's $2.72 million. Losses were -$47.68 million, 30.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $20.2, which is an increase of 148.92% from the latest price.
News
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focu...
Delcath Systems to Host First Quarter 2024 Earnings Call
QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announc...
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK , May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers ...
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y. , March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional onc...
Delcath Systems Closes $7 Million Private Placement
NEW YORK, March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the...
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
NEW YORK , March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...
Delcath Systems Announces $7 Million Private Placement
NEW YORK , March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...
Delcath Systems to Participate in Upcoming Investor Conferences
NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
NEW YORK , Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
NEW YORK , Jan. 23, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
NEW YORK , Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery System Results Support that Utilizing Delcath's HDS to Administer High-Dose Melphala...
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK , Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancer...
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced toda...
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers
Retrospective Comparison of Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (17 and 9.9 months...
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
NEW YORK , Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tha...
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023
NEW YORK , Oct. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participa...
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
Independent Investigator Study Compared Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (516 ...
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will particip...
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™
NEW YORK , Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod...